AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company discovering and developing novel antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that on February 27, 2017, the Company's board of directors granted its recently appointed Chief Commercial Officer, Janet Dorling, options to purchase an aggregate of 130,000 shares of the Company's common stock and 10,000 restricted stock units. Each stock option has an exercise price per share equal to $23.68, which was the closing trading price on February 27, 2017, the effective date of the grant. The stock options and restricted stock units were granted pursuant to the Company's 2014 Employment Commencement Incentive Plan, which was approved by the Company's board of directors in December 2014 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About Achaogen
Achaogen is a clinical-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of novel antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen’s lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. Achaogen’s plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. Plazomicin is the first clinical candidate from Achaogen’s gram-negative antibiotic discovery engine, and Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit www.achaogen.com.
Investor Contact: Hans Vitzthum 212.915.2568 [email protected] Media Contact: Denise Powell 510.703.9491 [email protected]
